Director Maintenance, Engineering AstraZeneca Sweden Operations
Joined AstraZeneca in 2019, has former work in different positions at Scania. During 8 years., in beginning 2000, I build a new business area in a daughter company where we offered services for business development with Lean and TPM.
Started as manager 1996 and has worked with different groups and organizations, from senior Lean consultants to >500 people in an automotive industry
Worked as Production manager, Maintenance manager and Lean/TPM consultant in different industries; automotive, mining, powerplants, paper mills.
Co-author of “Availability for maximized productivity ”
I have learned over the years that I need to be a good leader to be able to get the effect in tools and WoW for the people I work with. It starts with us humans.

The Pop in Your Job: What drives you? What is your passion?:
I´m driven by developing people and WoW to be more efficient and productive.
To invest time in people and give them the conditions to make the best result really give me a boost.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do. We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. These are reinforced by a strong focus on personalised healthcare capabilities, which aim to match medicines only to those patients who will benefit from them. Our teams also work alongside the world's leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies such as Modified RNA and CRISPR genome editing. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, visit www.astrazeneca.com.